Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EPS (Weighted Average and Diluted) (2019 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$1.85 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 28.47% year-over-year to -$1.85, compared with a TTM value of -$7.12 through Dec 2025, down 161.17%, and an annual FY2025 reading of -$7.12, down 161.17% over the prior year.
  • EPS (Weighted Average and Diluted) was -$1.85 for Q4 2025 at Agios Pharmaceuticals, down from -$1.79 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $26.95 in Q1 2021 and bottomed at -$1.93 in Q2 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.9, with a median of -$1.5 recorded in 2022.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 4110.94% in 2021, while the deepest fall reached 984.62% in 2021.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.07 in 2021, then surged by 871.43% to $0.68 in 2022, then plummeted by 352.94% to -$1.72 in 2023, then rose by 16.28% to -$1.44 in 2024, then decreased by 28.47% to -$1.85 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for AGIO at -$1.85 in Q4 2025, -$1.79 in Q3 2025, and -$1.93 in Q2 2025.